Paul Jeng
Stock Analyst at Guggenheim
(2.98)
# 1,329
Out of 5,182 analysts
9
Total ratings
87.5%
Success rate
48.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Maintains: Buy | $9 → $10 | $3.80 | +163.16% | 2 | Apr 6, 2026 | |
| CNTX Context Therapeutics | Reiterates: Buy | $5 | $2.49 | +100.80% | 2 | Mar 24, 2026 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $50 | $30.50 | +63.93% | 2 | Feb 18, 2026 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $10.43 | +82.17% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $31.05 | - | 1 | Sep 18, 2025 |
Adagene
Apr 6, 2026
Maintains: Buy
Price Target: $9 → $10
Current: $3.80
Upside: +163.16%
Context Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $5
Current: $2.49
Upside: +100.80%
IDEAYA Biosciences
Feb 18, 2026
Reiterates: Buy
Price Target: $50
Current: $30.50
Upside: +63.93%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $10.43
Upside: +82.17%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $31.05
Upside: -